secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001818382-25-000073
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte posts Q1 net income $39.1M; Symvess launch generates $147K revenue
---------------------------------------------------------------------------

- Q1 2025 revenue $517K ($147K from first Symvess commercial sales); no revenue in Q1 2024.
- Net income of $39.1M vs net loss of $31.9M YoY, driven by $62.3M non-cash remeasurement gain.
- Cash and equivalents $113.2M; $46.7M net from March public offering extended runway.
- Reduced workforce by ~31 employees; expects net savings of $13.8M in 2025, over $50M by 2026.
- 45 hospitals initiated Symvess VAC approval; 5 approved. On track for dialysis BLA in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/0001818382-25-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838225000073/huma-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001818382-25-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer